REUTERS
October 21, 2021 at 16:45 JST
A COVID-19 vaccine Shionogi & Co. is jointly developing with the National Institute of Infectious Diseases and a university (Provided by Shionogi & Co.)
Japan’s Shionogi & Co. Ltd. said on Wednesday it had started a Phase II/III clinical trial for its COVID-19 vaccine candidate.
The trial for the recombinant protein-based vaccine will take place in Japan and follows a Phase I trial in the country, Shionogi said in a statement. The company will also prepare to conduct multiple trials globally, it said.
Medicines usually have to pass three phases of clinical trials before they can be assessed for approval by regulators.
Separately, Daiichi Sankyo Co. said it planned to start a Phase II trial for its COVID-19 vaccine candidate next month.
The Japanese drugmaker is aiming for commercialization of the mRNA-type vaccine, known as DS-5670, in 2022, it said in a statement.
Stories about memories of cherry blossoms solicited from readers
Cooking experts, chefs and others involved in the field of food introduce their special recipes intertwined with their paths in life.
A series based on diplomatic documents declassified by Japan’s Foreign Ministry
A series on the death of a Japanese woman that sparked a debate about criminal justice policy in the United States
A series about Japanese-Americans and their memories of World War II
Here is a collection of first-hand accounts by “hibakusha” atomic bomb survivors.